https://mindmedicinelaw.com/briefing/filament-s-psilocybin-pex010-supply-deal-us-clinical-trial-implications-20261008-47964The Psychedelic Journalen2026-10-08T15:08:59.772047+00:00Filament's Psilocybin PEX010 Supply Deal: US Clinical Trial Implicationsfilament health, pex010, psilocybin supply, us clinical trials, fda compliance, gmp manufacturing, dea regulation, psychedelic research infrastructurehttps://mindmedicinelaw.com/briefing/fda-considers-ibogaine-trial-design-as-psychedelic-industry-eyes-commercializati-20261008-47961The Psychedelic Journalen2026-10-08T15:07:50.342274+00:00FDA Considers Ibogaine Trial Design as Psychedelic Industry Eyes Commercializationfda ibogaine trial design, psychedelic commercialization, compass pathways pricing, lsd brand names, psilocybin trademarks, psychedelic policy us, clinical trial safety, market access psychedelics, regulatory precedent, psychedelic therapy riskshttps://mindmedicinelaw.com/briefing/expanding-u-s-psychedelic-policy-public-health-and-non-clinical-use-20261007-47839The Psychedelic Journalen2026-10-08T15:09:32.478134+00:00Expanding U.S. Psychedelic Policy: Public Health and Non-Clinical Usepsychedelic policy, public health, non-clinical use, us drug law, harm reduction, indigenous practices, mental health, historical context, regulatory frameworks, community accesshttps://mindmedicinelaw.com/briefing/clearmind-engages-fda-psychedelic-therapy-policy-in-focus-20261007-47962The Psychedelic Journalen2026-10-08T15:09:14.073531+00:00Clearmind Engages FDA: Psychedelic Therapy Policy in Focusclearmind, fda, psychedelic therapy, regulatory policy, industry submissions, clinical trials, us drug regulation, stakeholder engagement, drug development, public healthhttps://mindmedicinelaw.com/briefing/2r-6r-hnk-reverses-ptsd-like-behaviors-in-female-rats-20261007-47881The Psychedelic Journalen2026-10-08T15:08:24.229961+00:00(2R,6R)-HNK Reverses PTSD-like Behaviors in Female Rats2r6r-hydroxynorketamine, ptsd, blast injury, female veterans, preclinical research, glutamate signaling, animal models, neurobehavioral disorders, clinical translationhttps://mindmedicinelaw.com/briefing/systematic-review-ketamine-for-bpd-depression-and-suicidality-20261007-47880The Psychedelic Journalen2026-10-08T15:08:07.351964+00:00Systematic Review: Ketamine for BPD, Depression, and Suicidalityketamine, borderline personality disorder, bpd, systematic review, depression, suicidality, clinical trials, psychedelic research, safety, evidence gapshttps://mindmedicinelaw.com/briefing/usc-clinical-trial-explores-psilocybin-and-mindfulness-for-depression-20261007-47963The Psychedelic Journalen2026-10-08T15:06:47.238212+00:00USC Clinical Trial Explores Psilocybin and Mindfulness for Depressionpsilocybin, mindfulness meditation, depression, clinical trial, usc, keck school of medicine, psychedelic-assisted therapy, fda, mental health, combination therapyhttps://mindmedicinelaw.com/briefing/clearmind-s-fda-submission-psychedelic-policy-dialogue-in-the-u-s-20261007-47786The Psychedelic Journalen2026-10-07T22:04:45.003925+00:00Clearmind’s FDA Submission: Psychedelic Policy Dialogue in the U.S.clearmind, fda, psychedelic policy, industry engagement, psychedelic regulation, clinical trials, u.s. federal law, drug development, public health, private sectorhttps://mindmedicinelaw.com/briefing/clearmind-s-psychedelic-therapy-recommendations-fda-policy-engagement-in-the-us-20261007-47626The Psychedelic Journalen2026-10-07T15:06:47.670175+00:00Clearmind’s Psychedelic Therapy Recommendations: FDA Policy Engagement in the USclearmind, fda policy, psychedelic therapy, industry submissions, us regulatory framework, drug development guidance, clinical trials, stakeholder engagementhttps://mindmedicinelaw.com/briefing/usc-launches-psilocybin-mindfulness-trial-for-depression-20261007-47628The Psychedelic Journalen2026-10-07T15:06:00.251441+00:00USC Launches Psilocybin-Mindfulness Trial for Depressionusc psilocybin trial, mindfulness and psychedelics, depression clinical research, psychedelic-assisted therapy, fda breakthrough therapy, academic psychedelic research, mental health policy, clinical trial protocolshttps://mindmedicinelaw.com/briefing/counselor-training-gaps-in-psychedelic-assisted-therapy-us-policy-and-practice-i-20261006-47840The Psychedelic Journalen2026-10-08T15:08:40.063527+00:00Counselor Training Gaps in Psychedelic-Assisted Therapy: US Policy and Practice Implicationspsychedelic-assisted therapy, counselor training, professional competencies, mental health policy, regulatory standards, public health risk, interdisciplinary collaboration, education gaps, clinical supervisionhttps://mindmedicinelaw.com/briefing/intranasal-penk-mscs-show-promise-for-opioid-dependence-in-rats-20261006-47563The Psychedelic Journalen2026-10-07T15:07:05.441283+00:00Intranasal PENK-MSCs Show Promise for Opioid Dependence in Ratsproenkephalin, mesenchymal stem cells, intranasal delivery, morphine dependence, neurotrophic factors, addiction treatment, preclinical research, substance use disorder, cell-based therapyhttps://mindmedicinelaw.com/briefing/ketamine-s-distinct-short-term-effects-on-insomnia-and-anxiety-in-trd-20261006-47561The Psychedelic Journalen2026-10-07T15:06:14.654925+00:00Ketamine’s Distinct Short-Term Effects on Insomnia and Anxiety in TRDketamine, treatment-resistant depression, insomnia, anxiety, clinical trial, psychiatric protocols, sleep mechanisms, FDA regulation, symptom-specific effectshttps://mindmedicinelaw.com/briefing/group-psychedelic-assisted-therapy-evidence-gaps-and-policy-implications-20261006-47516The Psychedelic Journalen2026-10-07T15:05:23.865407+00:00Group Psychedelic-Assisted Therapy: Evidence, Gaps, and Policy Implicationsgroup psychedelic therapy, systematic review, mental health, cost-effectiveness, peer support, randomized controlled trials, policy implications, clinical protocols, equity in therapy, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/optimi-health-s-phase-2-psilocybin-trial-advances-amid-market-pullback-20261006-47465The Psychedelic Journalen2026-10-06T22:06:52.473603+00:00Optimi Health’s Phase 2 Psilocybin Trial Advances Amid Market Pullbackoptimi health, psilocybin trial, phase 2 clinical trial, psychedelic sector, canadian regulation, market sentiment, health canada, investor risk, drug development, clinical research fundinghttps://mindmedicinelaw.com/briefing/ketamine-vs-esketamine-in-trd-clinical-policy-and-access-implications-20261006-47466The Psychedelic Journalen2026-10-06T22:06:31.352375+00:00Ketamine vs Esketamine in TRD: Clinical, Policy, and Access Implicationsketamine, esketamine, treatment-resistant depression, TRD, FDA approval, reimbursement, clinical trials, psychiatry, risk evaluation, real-world evidencehttps://mindmedicinelaw.com/briefing/dea-unveils-new-registration-forms-for-medical-cannabis-entities-20261006-47468The Psychedelic Journalen2026-10-06T22:05:27.272627+00:00DEA Unveils New Registration Forms for Medical Cannabis Entitiesdea registration, medical marijuana, federal oversight, cannabis policy, psychedelic regulation, compliance requirements, controlled substances, research licensing, diversion prevention, schedule ihttps://mindmedicinelaw.com/briefing/psychedelic-assisted-therapy-for-cancer-related-anxiety-evidence-and-policy-outl-20261005-47520The Psychedelic Journalen2026-10-07T15:07:22.155343+00:00Psychedelic-Assisted Therapy for Cancer-Related Anxiety: Evidence and Policy Outlookpsychedelic-assisted therapy, cancer-related anxiety, integrative oncology, clinical trials, mental health guidelines, psilocybin, emerging therapies, regulatory policy, methodological challengeshttps://mindmedicinelaw.com/briefing/amygdala-and-anxiety-threat-probability-not-uncertainty-drives-neural-response-20261005-47564The Psychedelic Journalen2026-10-07T15:06:31.170553+00:00Amygdala and Anxiety: Threat Probability, Not Uncertainty, Drives Neural Responseamygdala function, threat probability, anxiety neurobiology, clinical trial design, biomarker development, psychedelic research, extended amygdala, BST, Ce, translational neurosciencehttps://mindmedicinelaw.com/briefing/multidose-psilocybin-for-ocd-johns-hopkins-open-label-trial-insights-20261005-47518The Psychedelic Journalen2026-10-07T15:05:43.882804+00:00Multidose Psilocybin for OCD: Johns Hopkins Open-Label Trial Insightspsilocybin, obsessive-compulsive disorder, johns hopkins, clinical trial, multidose protocol, psychedelic therapy, y-bocs, regulatory pathways, safety and efficacy, treatment-resistant ocdhttps://mindmedicinelaw.com/briefing/ketamine-research-in-perioperative-neurocognitive-disorders-global-trends-and-ga-20261005-47388The Psychedelic Journalen2026-10-06T22:07:47.762615+00:00Ketamine Research in Perioperative Neurocognitive Disorders: Global Trends and Gapsketamine, perioperative neurocognitive disorders, esketamine, postoperative delirium, clinical trials, research standardization, bibliometric analysis, international collaboration, anesthesia, neurocognitive outcomeshttps://mindmedicinelaw.com/briefing/therapists-insights-on-psilocybin-assisted-depression-therapy-rct-preprint-revie-20261005-47389The Psychedelic Journalen2026-10-06T22:07:31.827498+00:00Therapists’ Insights on Psilocybin-Assisted Depression Therapy: RCT Preprint Reviewpsilocybin therapy, major depressive disorder, therapist perspectives, randomized controlled trial, psychotherapeutic support, clinical practice, qualitative research, policy implications, training standardshttps://mindmedicinelaw.com/briefing/iv-ketamine-for-suicidal-trd-real-world-case-series-insights-bangladesh-2024-20261005-47400The Psychedelic Journalen2026-10-06T22:07:13.179961+00:00IV Ketamine for Suicidal TRD: Real-World Case Series Insights (Bangladesh, 2024)iv ketamine, treatment-resistant depression, suicidal ideation, case series, real-world evidence, personalized psychiatry, bangladesh, clinical protocols, psychedelic research, safety and efficacyhttps://mindmedicinelaw.com/briefing/caution-in-psychedelic-therapy-adoption-clinical-evidence-gaps-20261005-47354The Psychedelic Journalen2026-10-06T22:05:48.601189+00:00Caution in Psychedelic Therapy Adoption: Clinical Evidence Gapspsychedelic clinical trials, implementation science, psilocybin, MDMA, psychiatric interventions, evidence-based medicine, safety monitoring, comparative effectiveness, policy implications, mental healthhttps://mindmedicinelaw.com/briefing/eeg-aperiodic-activity-as-biomarker-implications-for-psychiatric-trials-20261004-47401The Psychedelic Journalen2026-10-06T22:08:10.147860+00:00EEG Aperiodic Activity as Biomarker: Implications for Psychiatric Trialseeg biomarkers, aperiodic activity, psychiatric disorders, schizophrenia, depression, bipolar disorder, psychedelic clinical trials, biomarker validation, regulatory sciencehttps://mindmedicinelaw.com/briefing/ibogaine-induces-neural-repair-via-metabolic-preconditioning-in-mice-20261002-47907The Psychedelic Journalen2026-10-08T15:07:12.500550+00:00Ibogaine Induces Neural Repair via Metabolic Preconditioning in Miceibogaine, metabolic preconditioning, synaptic plasticity, neural repair, mitoKv1.3, sigma-2 receptor, preclinical study, psychedelic research, neuropsychiatric disorders, clinical trial designhttps://mindmedicinelaw.com/briefing/ketamine-misuse-in-sexual-assaults-legal-and-public-health-risks-in-the-u-s-20261002-47469The Psychedelic Journalen2026-10-06T22:06:09.588532+00:00Ketamine Misuse in Sexual Assaults: Legal and Public Health Risks in the U.S.ketamine, sexual assault, public health, regulatory oversight, dissociative anesthetics, controlled substances, clinical safeguards, forensic toxicology, university policyhttps://mindmedicinelaw.com/briefing/short-acting-tryptamines-clinical-evidence-and-regulatory-outlook-20261001-47857The Psychedelic Journalen2026-10-08T15:07:32.968046+00:00Short-Acting Tryptamines: Clinical Evidence and Regulatory Outlookshort-acting tryptamines, n,n-dmt, 5-meo-dmt, zalsupindole, treatment-resistant depression, phase 2b trial, neuroplasticity, hallucinogenic experience, regulatory strategy, adverse eventshttps://mindmedicinelaw.com/briefing/astrocytic-p2x7-receptors-and-depression-implications-for-novel-antidepressant-s-20261001-47398The Psychedelic Journalen2026-10-06T22:08:27.268559+00:00Astrocytic P2X7 Receptors and Depression: Implications for Novel Antidepressant Strategiesastrocytic p2x7 receptors, depression, major depressive disorder, mouse model, electroacupuncture, glial targets, neuropsychiatric research, biomarkers, psychedelic mechanisms, clinical translation